Pharmaceutical Regulatory Services — From First Filing to Full Lifecycle
Sub-headline: RABT Global delivers expert pharmaceutical regulatory services across all phases of the drug development and commercialisation lifecycle. From IND and CTA filings to NDA, MAA, ANDA submissions and post-approval lifecycle management.
Get expert pharmaceutical drug regulatory affairs support across FDA, EMA, MHRA, CDSCO, and global health authorities.
Pharmaceutical regulatory services are the engine behind every drug approval — from early clinical development through to commercial launch and lifecycle management. The pharmaceutical regulatory affairs landscape is complex, highly regulated, and constantly evolving. A single missed requirement or poorly structured dossier can set a product back by months or derail an entire regulatory programme.
At RABT Global, our pharmaceutical regulatory services are delivered by a team of experienced regulatory affairs professionals who specialise in drug regulatory affairs across all major therapeutic areas and regulatory frameworks. We provide end-to-end pharma regulatory services — from regulatory strategy and clinical trial application (CTA/IND) support, through full CTD dossier preparation, eCTD submission, and global product registration, to post-approval lifecycle management and ongoing pharmaceutical regulatory affairs consulting.
Our pharmaceutical regulatory services are trusted by pharmaceutical, biotech, and generic drug companies operating across the USA, EU, UK, India, and emerging markets. Whether you need regulatory consulting for pharma companies seeking a first NDA approval, or a specialist regulatory affairs service provider to manage a complex multi-market portfolio, RABT Global has the expertise to deliver.
Full-Service vs Partial Pharma Regulatory Support
| RABT Global Full-Service Pharma RA | Typical Partial Regulatory Service |
|---|---|
| Strategy + submission + post-approval — integrated | Submission support only — no strategy or lifecycle |
| Multi-market regulatory sequencing | Single-market focus |
| In-house medical writing for clinical modules | Outsourced writing, integration risk |
| Dedicated pharmaceutical regulatory affairs team | Shared generalist resources |
| eCTD publishing in-house | Third-party publisher dependency |
| Regulatory intelligence on drug regulations | Reactive to client-identified changes |
Our Pharmaceutical Regulatory Services Portfolio
Pharmaceutical Regulatory Strategy
strategic regulatory pathway planning for new chemical entities (NCEs), generics, biosimilars, and biologics
IND / CTA Preparation & Submission
Investigational New Drug (IND) and Clinical Trial Application (CTA) preparation and submission support
NDA / MAA / ANDA Submissions
complete dossier preparation and submission for drug marketing authorisation applications globally
CTD Dossier Compilation
Module 1–5 CTD preparation, quality, non-clinical, and clinical documentation
eCTD Publishing & Submission Management
eCTD lifecycle publishing, validation, and health authority submission
Drug Regulatory Affairs for Generics
ANDA preparation, ASMF/DMF management, bioequivalence study support
Biosimilar Regulatory Strategy
EMA, FDA, and global biosimilar approval pathway planning and submission support
Post-Approval Variations & Renewals
Type I/II/III variations, Prior Approval Supplements, licence renewals
Global Drug Registration
pharmaceutical product registration in GCC, CDSCO, TGA, Health Canada, and other markets
What are Pharmaceutical Regulatory Services?
Pharmaceutical regulatory services are professional services that support pharmaceutical and biotech companies in navigating the regulatory requirements needed to develop, register, and commercialise drug products worldwide. These services include regulatory strategy, IND/CTA filing, NDA/MAA/ANDA preparation, eCTD submission, post-approval lifecycle management, and global pharmaceutical regulatory affairs consulting — provided by specialist firms like RABT Global.
Pharmaceutical Regulatory Services — FAQs
A: Pharmaceutical regulatory affairs consulting covers all aspects of regulatory management for drug products — including regulatory strategy, clinical trial authorisations, marketing application preparation (NDA, MAA, ANDA), agency submissions, post-approval lifecycle management, and ongoing regulatory compliance monitoring. RABT Global provides end-to-end pharma regulatory services across all these areas.
A: RABT Global’s pharmaceutical regulatory services cover FDA (USA), EMA and national competent authorities (EU), MHRA (UK), CDSCO (India), SFDA (Saudi Arabia), MOHAP (UAE), Health Canada, TGA (Australia), and other global regulatory agencies. We provide global pharmaceutical regulatory support across all major markets.
A: Yes. Our drug regulatory consulting services include specialist support for generic pharmaceutical development — including ANDA preparation, Active Substance Master File (ASMF/DMF) management, bioequivalence study regulatory support, and generic product registration across global markets.
A: Yes. RABT Global provides dedicated biosimilar regulatory strategy and regulatory affairs service provider capabilities for biological products — including comparability studies support, EMA and FDA biosimilar pathway planning, and full dossier preparation for biosimilar marketing authorisation applications.
Accelerate Your Pharmaceutical Regulatory Programme with RABT Global
Expert pharmaceutical regulatory services. End-to-end pharma regulatory affairs. Global regulatory support across every major market.